Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 71.28 USD 0.32% Market Closed
Market Cap: 11.3B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Intrinsic Value

The intrinsic value of one TECH stock under the Base Case scenario is 54.19 USD. Compared to the current market price of 71.28 USD, Bio-Techne Corp is Overvalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TECH Intrinsic Value
54.19 USD
Overvaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bio-Techne Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TECH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TECH?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Bio-Techne Corp

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Bio-Techne Corp

Provide an overview of the primary business activities
of Bio-Techne Corp.

What unique competitive advantages
does Bio-Techne Corp hold over its rivals?

What risks and challenges
does Bio-Techne Corp face in the near future?

Has there been any significant insider trading activity
in Bio-Techne Corp recently?

Summarize the latest earnings call
of Bio-Techne Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bio-Techne Corp.

Provide P/S
for Bio-Techne Corp.

Provide P/E
for Bio-Techne Corp.

Provide P/OCF
for Bio-Techne Corp.

Provide P/FCFE
for Bio-Techne Corp.

Provide P/B
for Bio-Techne Corp.

Provide EV/S
for Bio-Techne Corp.

Provide EV/GP
for Bio-Techne Corp.

Provide EV/EBITDA
for Bio-Techne Corp.

Provide EV/EBIT
for Bio-Techne Corp.

Provide EV/OCF
for Bio-Techne Corp.

Provide EV/FCFF
for Bio-Techne Corp.

Provide EV/IC
for Bio-Techne Corp.

Show me price targets
for Bio-Techne Corp made by professional analysts.

What are the Revenue projections
for Bio-Techne Corp?

How accurate were the past Revenue estimates
for Bio-Techne Corp?

What are the Net Income projections
for Bio-Techne Corp?

How accurate were the past Net Income estimates
for Bio-Techne Corp?

What are the EPS projections
for Bio-Techne Corp?

How accurate were the past EPS estimates
for Bio-Techne Corp?

What are the EBIT projections
for Bio-Techne Corp?

How accurate were the past EBIT estimates
for Bio-Techne Corp?

Compare the revenue forecasts
for Bio-Techne Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bio-Techne Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bio-Techne Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bio-Techne Corp compared to its peers.

Compare the P/E ratios
of Bio-Techne Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Bio-Techne Corp with its peers.

Analyze the financial leverage
of Bio-Techne Corp compared to its main competitors.

Show all profitability ratios
for Bio-Techne Corp.

Provide ROE
for Bio-Techne Corp.

Provide ROA
for Bio-Techne Corp.

Provide ROIC
for Bio-Techne Corp.

Provide ROCE
for Bio-Techne Corp.

Provide Gross Margin
for Bio-Techne Corp.

Provide Operating Margin
for Bio-Techne Corp.

Provide Net Margin
for Bio-Techne Corp.

Provide FCF Margin
for Bio-Techne Corp.

Show all solvency ratios
for Bio-Techne Corp.

Provide D/E Ratio
for Bio-Techne Corp.

Provide D/A Ratio
for Bio-Techne Corp.

Provide Interest Coverage Ratio
for Bio-Techne Corp.

Provide Altman Z-Score Ratio
for Bio-Techne Corp.

Provide Quick Ratio
for Bio-Techne Corp.

Provide Current Ratio
for Bio-Techne Corp.

Provide Cash Ratio
for Bio-Techne Corp.

What is the historical Revenue growth
over the last 5 years for Bio-Techne Corp?

What is the historical Net Income growth
over the last 5 years for Bio-Techne Corp?

What is the current Free Cash Flow
of Bio-Techne Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bio-Techne Corp.

Business Breakdown

Bio-Techne Corp. stands at the forefront of scientific progress, intertwining innovation with essential biotechnology solutions. Founded in 1976 and headquartered in Minneapolis, the company has evolved from its roots in producing protein research reagents to a diversified powerhouse, supporting the life sciences and clinical diagnostics sectors. Bio-Techne's expansive portfolio encompasses cutting-edge tools and technologies allowing researchers to delve deeper into cellular analysis, gene expression, and molecular diagnostics. With brands like R&D Systems, Novus Biologicals, and ProteinSimple under its belt, the company empowers scientists worldwide to unlock new discoveries, simulate comp...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bio-Techne Corp

Current Assets 617.4m
Cash & Short-Term Investments 152.9m
Receivables 241.4m
Other Current Assets 223.2m
Non-Current Assets 2.1B
PP&E 342.4m
Intangibles 1.5B
Other Non-Current Assets 264.3m
Current Liabilities 159.4m
Accounts Payable 38m
Accrued Liabilities 87.6m
Other Current Liabilities 33.8m
Non-Current Liabilities 475.6m
Long-Term Debt 319m
Other Non-Current Liabilities 156.6m
Efficiency

Earnings Waterfall
Bio-Techne Corp

Revenue
1.2B USD
Cost of Revenue
-389.3m USD
Gross Profit
769.7m USD
Operating Expenses
-521.3m USD
Operating Income
248.5m USD
Other Expenses
-80.4m USD
Net Income
168.1m USD

Free Cash Flow Analysis
Bio-Techne Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Bio-Techne began fiscal 2025 with a solid performance, reporting a 5% year-over-year revenue increase to $289.5 million. Adjusted EPS was $0.42, slightly up from $0.41 last year. The Diagnostics and Spatial Biology segment shone with a 14% jump in sales, while Protein Sciences saw a modest 1% growth. Strong demand in cell and gene therapy fueled optimism, with mid-single-digit growth expected in Q2. However, operating margins were impacted by product mix and reinstated compensation, leading to a guidance of 200-300 basis points lower for the first half. Overall, expectations remain intact, anticipating high single-digit exit rates by year-end.

What is Earnings Call?
Fundamental Scores

TECH Profitability Score
Profitability Due Diligence

Bio-Techne Corp's profitability score is 61/100. The higher the profitability score, the more profitable the company is.

61/100
Profitability
Score

Bio-Techne Corp's profitability score is 61/100. The higher the profitability score, the more profitable the company is.

TECH Solvency Score
Solvency Due Diligence

Bio-Techne Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Long-Term Solvency
Short-Term Solvency
87/100
Solvency
Score

Bio-Techne Corp's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TECH Price Targets Summary
Bio-Techne Corp

Wall Street analysts forecast TECH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TECH is 87.11 USD with a low forecast of 75.75 USD and a high forecast of 99.75 USD.

Lowest
Price Target
75.75 USD
6% Upside
Average
Price Target
87.11 USD
22% Upside
Highest
Price Target
99.75 USD
40% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TECH?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for TECH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TECH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

TECH News

Other Videos

Profile

Bio-Techne Corp Logo
Bio-Techne Corp

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

11.3B USD

Dividend Yield

0.45%

Description

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. The company is headquartered in Minneapolis, Minnesota and currently employs 2,600 full-time employees. The firm operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.

Contact

MINNESOTA
Minneapolis
614 McKinley Pl NE
+16123798854.0
www.bio-techne.com

IPO

1989-02-09

Employees

2 600

Officers

CEO, President & Director
Mr. Kim Kelderman
Executive VP of Finance & CFO
Mr. James T. Hippel
Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer
Mr. Shane Bohnen
President of Protein Sciences Segment
Mr. William A. Geist
President of Diagnostics & Genomics
Dr. Matthew F. McManus M.D., MBA, Ph.D.
VP & CTO
Dr. Gary J. Latham Ph.D.
Show More
Senior Director of Investor Relations & Corporate Development
David Clair
Vice President of Sales and Marketing
Mr. Gerry Andros
Senior Vice President of Strategy & Corporate Development
Mr. Martin Wirtz
Senior VP & Chief Human Resources Officer
Ms. Cheryl Bethune
Show Less

See Also

Discover More
What is the Intrinsic Value of one TECH stock?

The intrinsic value of one TECH stock under the Base Case scenario is 54.19 USD.

Is TECH stock undervalued or overvalued?

Compared to the current market price of 71.28 USD, Bio-Techne Corp is Overvalued by 24%.

Back to Top